Hepatocellular carcinoma (HCC) is the fifth cause of death by cancer worldwide ([Parkin, 2001](#bib16){ref-type="other"}). Many symptomatic HCCs are diagnosed in advanced stage and cannot be treated, so the prognosis is generally poor ([Wong *et al*, 2000](#bib26){ref-type="other"}; [Bruix and Llovet, 2002](#bib3){ref-type="other"}). By the accumulation of knowledge of the risk factors and the prevalence of HCC surveillance, the proportion of HCC diagnosed in early stage and that can be treated by local ablation therapies or surgery has increased ([Bolondi, 2003](#bib2){ref-type="other"}; [Adams *et al*, 2004](#bib1){ref-type="other"}; [Trevisani *et al*, 2004](#bib23){ref-type="other"}).

In spite of the early detection of HCC, many patients die of complications of severe cirrhosis without any active treatment ([Ikai *et al*, 2007](#bib8){ref-type="other"}). According to the algorithms of the treatment of HCC recommended by groups in Europe and Japan ([Bruix *et al*, 2001](#bib4){ref-type="other"}; [Llovet, 2005](#bib12){ref-type="other"}; [Makuuchi and Kokudo, 2006](#bib14){ref-type="other"}), HCC patient with Child C cirrhosis ([Pugh *et al*, 1973](#bib18){ref-type="other"}) is a candidate for liver transplantation or best supportive care (BSC). However, even though HCC meets the Milan criteria, many patients do not receive liver transplantation because of the shortage of donors or advanced age ([United Network for Organ Sharing, 2006](#bib25){ref-type="other"}). Although there is regional variability, patients diagnosed with HCC in the background of hepatitis C virus infection are usually elderly ([Parkin, 2001](#bib16){ref-type="other"}). In Japan, the mean age of patients is 66.6 years old ([Ikai *et al*, 2007](#bib8){ref-type="other"}); therefore, a large number of the patients are outside the liver transplantation criteria and receive only BSC.

Local ablation therapies and transcatheter arterial chemoembolisation (TACE) are known to be useful for HCC treatment with preserved liver function ([Llovet *et al*, 2003](#bib13){ref-type="other"}). Nevertheless, these therapies for patients with Child C cirrhosis are not recommended because of reported severe adverse events. However, there is lack of knowledge on prognostic factors on the effectiveness of active treatment, except liver transplantation, in HCC patients with Child C cirrhosis ([Llovet, 2005](#bib12){ref-type="other"}). Therefore, it is very important to identify factors influencing outcomes of cirrhotic patients affected by HCC who cannot be treated by liver transplantation.

In this study, we retrospectively examined the clinical course of HCC patients with Child C cirrhosis and analysed their prognostic factors.

PATIENTS AND METHODS
====================

Patients
--------

Between January 1996 and September 2006 among 3330 consecutive newly diagnosed HCC patients who were admitted to our department and affiliated hospitals, 186 individuals had Child C cirrhosis. Five patients were excluded because of a lack of clinical data, 24 were excluded because they underwent liver transplantation, and the remaining patients (*n*=157) were enrolled in this study. Informed consent was obtained from all patients for use of their clinical data. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki, and was approved by the ethical committees of the institutes.

Diagnosis
---------

One hundred and forty-one patients were diagnosed as having HCC by imaging modalities, such as angiography, computed tomography (CT), and magnetic resonance imaging (MRI). Diagnostic criteria for HCC via imaging was based on previous reports of hyperattenuation at the arterial phase, hypoattenuation at the portal phase in dynamic CT (section thickness=5--8 mm) or MRI, and tumour stain on angiography ([Honda *et al*, 1993](#bib7){ref-type="other"}). The remaining 16 patients with hepatic masses who did not satisfy the above criteria underwent ultrasound (US)-guided fine-needle biopsy with histologically confirmed HCC.

Treatments
----------

As there is no clear evidence that active treatment of HCC improves the survival of patients with Child C cirrhosis, all the patients were informed that the potential treatment benefits were unknown and the risks of the treatments were higher than in patients with Child A/B cirrhosis. We conducted local ablation therapy, TACE, or transcatheter arterial chemoinfusion (TAI) only when patients consented to undergo these interventions. Percutaneous ethanol injection therapy, radiofrequency ablation, and microwave coagulation therapy were performed in 18, 4, and 1 patients, respectively. All HCCs treated by local ablation therapy were less than 3 cm in diameter and less than three tumours, except three single large HCC with diameters between 3.0 and 3.5 cm. There are two major differences of our treatment algorithm for patients with Child C cirrhosis from that for patients with Child A/B cirrhosis. Surgical resection was not chosen and indication for local ablation therapy was stricter. When a tumour protruded from the liver surface, attached to the adjacent organs such as gall bladder, or a tumour was not confirmed well by ultrasonography, local ablation therapies were not performed. The therapies were also avoided when uncontrollable ascites was present. We included transcatheter arterial embolisation (TAE) in the group undergoing TACE, because the number of patients who received TAE was small and no clear difference in the treatment effect was reported in previous studies ([Camma *et al*, 2002](#bib5){ref-type="other"}). Transcatheter arterial chemoembolisation was not chosen principally in cases of severe portal vein tumour thrombus (PVTT). Transcatheter arterial chemoembolisation and TAI were performed supraselectively in the most peripheral accessible feeding artery to avoid irreversible liver failure. When the treatment might cause immediate irreversible liver failure or severe complications, we did not perform any active treatments irrespective of the patients\' wishes, except emergency TACE for HCC rupture.

Follow-up
---------

Biochemical liver function tests and US, dynamic CT, or MRI were performed at least every 3 months after the treatment. Re-treatment was performed depending on patients\' conditions, tumour stage and background liver function, according to the same clinical indications as for the first intervention.

Statistical analysis
--------------------

The Kruskal--Wallis test was used to compare the continuous data and the *χ*^2^ test was used to compare categorical data. Cox proportional hazards regression analysis was used to analyse the prognostic factors. Factors exhibiting significant values in univariate analysis and effect of the treatments were further analysed by multivariate analysis. The propensity score of choosing each treatment was calculated, followed by matching each treatment group and BSC group according to a greedy matching technique ([Parsons, 2001](#bib17){ref-type="other"}). For calculation of the propensity score, following variables (cutoffs) were used: total bilirubin (\<2, 2--3, \>3, mg per dl), tumour size (\<20, 20--30, \>30, mm), tumour number (1, \>1), PVTT (absent, present). The survival of matched patients was compared by the Kaplan--Meyer method and the differences were evaluated by the log-lank test. SAS (version 9.1.3) and JMP (version 5.0.1) software packages (SAS Institute, Cary, NC, USA) were used for analyses, and *P*\<0.05 was considered significant. Bonferroni correction was used for multiple comparisons of propensity score-matched analyses and *P*\<0.05/3 was considered significant.

RESULTS
=======

Clinical characteristic of the patients
---------------------------------------

Twenty-three patients (14.7%) were treated by local ablation therapy, 27 (17.2%) by TACE, and 19 (12.1%) by TAI. The remaining patients (*n*=88, 56.1%) did not receive any of these treatments (BSC group). One- and 3-year survival of patients was 42.6 and 14.0%, respectively.

The characteristics of all patients are reported in [Table 1](#tbl1){ref-type="table"}. There was no difference in sex and age among these groups. The positive rate of hepatitis C virus antibody was low (55.7%) in the BSC group. Background liver function (Child-Pugh score) was worse and the tumours were more advanced (tumour size, tumour number, alpha-fetoprotein (AFP), and PVTT) in the BSC group than in other groups. Eighteen patients could be re-treated by local ablation therapies, TAE, or TAI.

Risk factors for survival of HCC patients with Child C cirrhosis
----------------------------------------------------------------

Among 17 parameters and treatment modalities, high bilirubin (\>3 mg dl^−1^), the presence of uncontrollable ascites, and a high platelet count (\>8 × 10^4^ mm^−3^), so-called background liver factors, as well as multiple tumour number, large tumour (\>3 cm), high AFP (\>400 ng ml^−1^), and the presence of PVTT, so-called tumour factors, were significant risk factors for death in univariate analysis in [Table 2](#tbl2){ref-type="table"}. Conversely, TACE and local ablation therapy were associated with better survival. As shown in [Table 3](#tbl3){ref-type="table"}, multivariate analysis revealed that all background factors and tumour factors that were significant in univariate analysis were also significant risk factors. Regarding therapies, only TACE was a significant negative risk factor for death by multivariate analysis.

Survival of patients in different therapeutic groups
----------------------------------------------------

One-year (3-year) survival of patients receiving local ablation therapy, TACE, TAI, and BSC was 69.1 (41.3), 62.5 (29.8), 43.9 (12.6), and 27.7% (3.8%), respectively (*P*\<0.001, [Figure 1](#fig1){ref-type="fig"}). To estimate the effect of treatments, the clinical background of the patients in each group was adjusted by propensity scores, and the survival of treated groups was compared with the BSC group. Numbers of the score-matched pairs were 25, 19, and 19 for TACE *vs* BSC group, local ablation therapy *vs* BSC group, and TAI *vs* BSC group, respectively. One patient in the BSC group for the comparison with TACE group had a main portal vein thrombus. While survival in the TACE group was significantly better than in the BSC group (*P*=0.009, [Figure 2](#fig2){ref-type="fig"}), no differences in survival were observed between the local ablation group and BSC group (*P*=0.782, [Figure 3](#fig3){ref-type="fig"}), and between TAI group and BSC group (*P*=0.237, [Figure 4](#fig4){ref-type="fig"}).

DISCUSSION
==========

The prognosis of HCC patients with Child C cirrhosis is well known to be poor; however, there is little information about the prognostic factors among patients and the effect of active treatment, except liver transplantation ([Llovet, 2005](#bib12){ref-type="other"}). In this study, we clearly demonstrated that high total bilirubin (\>3 mg dl^−1^) and the presence of uncontrollable ascites, categorised as background liver factors, were independent factors for poor prognosis in HCC patients with Child C cirrhosis. In addition, tumour factors such as tumour size (\>3 cm), tumour number (multiple), AFP (\>400 ng ml^−1^), and PVTT were also independent prognostic factors. These factors were quite similar to the reported prognostic factors for HCC, which include chronic hepatitis and Child A or B cirrhosis ([Sala *et al*, 2005](#bib19){ref-type="other"}). High platelet count also correlated with poor prognosis. Platelet is known to decrease according to the advancement of cirrhosis. Therefore, it is possible that the liver in patients with high platelet count is not cirrhotic and the liver function is disturbed by very advanced HCC, which can be a reason of poor prognosis. This explanation was strengthened by a result in this study. The size of HCC in patients with high platelet count was significantly larger than that in patients with low platelet count (data not shown).

The contribution of tumour factors to HCC patients with Child C cirrhosis indicated that HCC treatment might prolong survival even though the patients suffered from Child C cirrhosis. The results of multivariate analysis of the treatments and of propensity score-matched survival curves support this hypothesis. The relative risk for patients undergoing TACE was 0.50 and survival of this group was better than that of BSC (*P*=0.009). Only two patients died within a month and had been treated by TACE because of HCC rupture (data not shown). Although TACE might be an eligible method for the treatment of HCC with Child C cirrhosis, the results do not indicate that TACE is effective in all Child C patients. Transcatheter arterial chemoembolisation was selected for patients without severe portal vein thrombus and with relatively good liver function in this analysed population. The medians of bilirubin and prothrombin time in TACE group were 1.9 mg dl^−1^ and 64.2%, respectively.

While TACE showed a beneficial effect, local ablation therapy did not prolong survival. One possible reason is that the deterioration of liver function to death is much faster than tumour progression. The reported 1-year local recurrence rate of HCC in patients treated by local ablation therapy was low (2--18%) ([Lin *et al*, 2005](#bib11){ref-type="other"}; [Tateishi *et al*, 2006](#bib21){ref-type="other"}; [Kim *et al*, 2006b](#bib10){ref-type="other"}), whereas the 1-year survival rate of Child C patients treated by local ablation therapy was 69.1%, indicating that many patients died without recurrence of HCC. Although no effect of local ablation therapy was observed, therapy including RFA could be used for decompensated liver cirrhosis ([Kim *et al*, 2006a](#bib9){ref-type="other"}) and it is possible that it might be beneficial in special circumstances, such as when minute growth of the tumour immediately results in the occlusion of major critical vessels.

Several studies have addressed the characters of HCC with decompensated cirrhosis ([Nagasue *et al*, 1999](#bib15){ref-type="other"}; [Ueno *et al*, 2002](#bib24){ref-type="other"}; [Toyoda *et al*, 2005](#bib22){ref-type="other"}). [Ueno *et al* (2002)](#bib24){ref-type="other"} reported that high albumin, lack of oesophageal varices, small tumour, single tumour, and low AFP were survival factors for HCC patients with decompensated liver cirrhosis. The study included many Child B cirrhosis patients (over 85%); however, the results were quite similar to our data with Child C cirrhosis. [Toyoda *et al* (2005)](#bib22){ref-type="other"} reported risk factors for HCC patients with Child C cirrhosis and beneficial effect of treatment; however, the study included old cases and details of the treatment were not described. Regarding therapies, BSC was recommended for the treatment of HCC with decompensated cirrhosis, except in transplantation-eligible cases, by the algorithms of HCC treatment demonstrated by groups in Europe and Japan ([Bruix *et al*, 2001](#bib4){ref-type="other"}; [Llovet, 2005](#bib12){ref-type="other"}; [Makuuchi and Kokudo, 2006](#bib14){ref-type="other"}), while there are several reports indicating the usefulness or safety of operation, RFA, and TACE for patients with decompensated liver cirrhosis ([Nagasue *et al*, 1999](#bib15){ref-type="other"}; [Ueno *et al*, 2002](#bib24){ref-type="other"}; [Kim *et al*, 2006a](#bib9){ref-type="other"}). Prospective randomised study is the best method to know the benefit of these therapies for HCC patients with Child C cirrhosis; however, it is ethically difficult now because no clear evidence of the beneficial effect of active treatments was reported and most of the guidelines for the treatment of HCC did not recommend these therapies except transplantation. Our study was a retrospective cohort study, the patient groups were heterogenous and the number of patients in each arm was quite limited; however, we clearly indicates the possibility of adopting TACE for the treatment of HCC in patients with Child C cirrhosis by both multivariate Cox proportional hazard model and propensity score-matched analyses.

Recently, improvement of liver function in patients with decompensated liver cirrhosis by anti-hepatitis virus therapy such as lamivudine or adefovir dipivoxil was reported ([Hiraoka *et al*, 2005](#bib6){ref-type="other"}; [Takamura *et al*, 2007](#bib20){ref-type="other"}). Adoption of these anti-viral therapies can reduce patient mortality from liver failure so that the treatment effect of local ablation therapy may improve, resulting in increased candidates for active treatment of HCC with Child C cirrhosis.

In this study, we demonstrated that tumour factors as well as background liver factors were risk factors even in HCC patients with Child C cirrhosis, and that TACE can be effective in a very selected group of patients. A randomised controlled study is needed to expand the eligible criteria for active treatment.
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###### 

Clinical background of 157 patients

                                      **TACE**             **TAI**            **Local**            **BSC**       ***P*-value**
  ------------------------------ ------------------- ------------------- ------------------- ------------------- ---------------
  Patient number                     27 (17.2%)          19 (12.1%)          23 (14.7%)          88 (56.1%)       
  Sex (male)                         21 (77.8%)          15 (79.0%)          16 (69.6%)          64 (72.7%)      0.085
  Age (years)                        66 (55--70)         65 (60--68)         59 (52--64)         62 (56--70)     0.275
  HCVAb (positive)                   24 (88.9%)          15 (79.0%)          18 (78.3%)          49 (55.7%)      0.003
  HBsAg (positive)                    2 (7.4%)            2 (10.5%)           4 (17.4%)          25 (28.4%)      0.061
  Total bilirubin (mg per dl)      1.9 (1.2--2.5)      2.4 (2.1--3.1)      2.8 (2.1--3.4)      3.5 (2.2--4.8)    \<0.001
  Albumin (g per dl)               2.6 (2.5--2.7)      2.5 (2.3--2.9)      2.7 (2.5--3.0)      2.6 (2.2--2.9)    0.213
  AST (IU per l)                    61 (50--105)        83 (65--111)        72 (50--103)        80 (46--188)     0.426
  ALT (IU per l)                     41 (35--61)         57 (40--76)         48 (40--68)         44 (36--86)     0.550
  Platelet ( × 10^4^ mm^−3^)       8.8 (5.7--11.6)      7 (5.1--9.7)       5.7 (4.7--7.2)      9.4 (6.1--13.7)   0.004
  Prothrombin time (%)            64.2 (50.0--68.9)    61 (55.6--66.3)    54.4 (49.4--62.0)   54.1 (45.0--63.0)  0.012
  Creatinine (mg per dl)          0.81 (0.70--0.96)   0.76 (0.66--1.10)   0.77 (0.60--0.90)   0.78 (0.61--1.03)  0.593
  Ascites (present)                  13 (48.2%)           8 (42.1%)           5 (21.7%)          60 (68.2%)      \<0.001
  Encephalopathy (present)           12 (44.5%)           9 (43.4%)           8 (34.8%)          40 (45.5%)      0.811
  Tumour number (single)              9 (33.3%)           7 (36.8%)          17 (73.9%)          28 (31.8%)      0.002
  Tumour size (mm)                   38 (23--53)         32 (26--65)         20 (17--29)       51.5 (30--100)    \<0.001
  AFP (ng per ml)                   32 (13--1250)       81 (13--706)         21 (9--106)       188 (26--8660)    0.001
  Portal invasion (present)           7 (25.9%)           6 (31.6%)            0 (0%)            49 (55.7%)      \<0.001
  Child-Pugh score (10/11/12∼)         15/11/1             11/6/2              13/7/3             26/23/39       \<0.001

Abbreviations: AFP=alpha-fetoprotein; ALT=alanine aminotransferase; AST=aspartate aminotransferase; HBsAg=hepatitis B virus surface-antigen; HCVAb=hepatitis C virus-antibody.

All variables are shown in median (interquartile range) unless otherwise noted.

###### 

Univariate analysis of the prognostic factors of HCC patients with Child C cirrhosis

                                     **RR**   **95% CI**   ***P*-value**
  --------------------------------- -------- ------------ ---------------
  Sex (male)                          1.16    0.78--1.78       0.457
  Age (per 10years)                   1.11    0.91--1.36       0.264
  HCVAb (positive)                    0.96    0.65--1.44       0.869
  HBsAg (positive)                    1.21    0.75--1.88       0.404
  Total bilirubin (\>3 mg dl^−1^)     2.14    1.48--3.09      \<0.001
  Albumin (\>3 g dl^−1^)              1.46    0.94--2.21       0.090
  AST (\>40 IU l^−1^)                 1.04    0.66--1.72       0.843
  ALT (\>40 IU l^−1^)                 1.31    0.90--1.92       0.148
  Platelets (\>8 × 10^4^ mm^−3^)      2.23    1.52--3.26      \<0.001
  Prothrombin time (\>50%)            1.24    0.84--1.86       0.275
  Creatinine (\>1 mg dl^−1^)          1.16    0.74--1.76       0.487
  Ascites (uncontrollable)            2.46    1.67--3.66      \<0.001
  Encephalopathy (present)            0.98    0.67--1.41       0.926
  Tumour number (multiple)            2.21    1.49--3.31      \<0.001
  Tumour size (\>30 mm)               3.81    2.54--5.83      \<0.001
  AFP (\>400 ng ml^−1^)               2.49    1.69--3.63      \<0.001
  Portal invasion (present)           3.90    2.64--5.76      \<0.001
  TACE                                0.56    0.33--0.91       0.019
  Local ablation                      0.42    0.24--0.70      \<0.001
  TAI                                 0.97    0.54--1.61       0.915

Abbreviations: TACE=transcatheter arterial chemoembolisation; TAI=transcatheter arterial chemoinfusion. Other abbreviations are as listed in [Table 1](#tbl1){ref-type="table"}.

###### 

Multivariate analysis of the prognostic factors of HCC patients with Child C cirrhosis

                                     **RR**   **95% CI**   ***P*-value**
  --------------------------------- -------- ------------ ---------------
  Total bilirubin (\>3 mg dl^−1^)     2.94    1.90--4.58      \<0.001
  Platelets (\>8 × 10^4^ mm^−3^)      1.77    1.11--2.84       0.016
  Ascites (uncontrollable)            1.80    1.14--2.87       0.010
  Tumour number (multiple)            1.67    1.06--2.66       0.025
  Tumour size (\>30 mm)               3.00    1.74--5.24      \<0.001
  AFP (\>400 ng ml^−1^)               1.68    1.05--2.67       0.029
  Portal invasion (present)           1.77    1.09--2.85       0.019
  TACE                                0.50    0.27--0.89       0.019
  Local ablation                      1.02    0.51--1.96       0.944
  TAI                                 0.64    0.33--1.16       0.152

Abbreviations are as listed in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}.
